Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)
机构：[1]Department of Oncology, Baiyun Hospital of The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.[2]Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.[3]Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.
This planned multicenter observational study will evaluate the overall survival of those undergoing integrated Chinese and Western medicine for stage IIIb-IVb non-small cell lung cancer and analyze the factors related to the prognosis.The prospective cohort will enroll patients with stage IIIb-IVb NSCLC from March 1, 2019, to December 31, 2025, and follow them for 5 years. We plan to collect data on the patients' demographics, treatment, overall survival, and factors related to the prognosis.The institutional review board and ethics committee reviewed the study protocol. All patients will provide informed consent before enrollment.Trial registration number: ChiCTR1900021430.
基金：
a pilot project of the Chinese Medicine
and Western Medicine Clinical Collaboration for Major Difficult
Diseases—“Lung Cancer” of the National Administration of
Traditional Chinese Medicine: 2019 Project for building evidencebased
practice capacity for TCM (no. 2019XZZX-ZL001), and a prediction model of Integrated Chinese and Western Medicine in
the treatment of stage IIIb-IVb non-small cell lung cancer based
on the real world (Research Projects of Guangdong Provincial
Bureau of Traditional Chinese Medicine, no. 20201095).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区全科医学与补充医学4 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|3 区全科医学与补充医学4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Oncology, Baiyun Hospital of The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.[2]Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Lin Jietao,Sun Lingling,Chen Hanrui,et al.Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)[J].Integrative cancer therapies.2023,22:15347354231185109.doi:10.1177/15347354231185109.
APA：
Lin Jietao,Sun Lingling,Chen Hanrui,Chen Wenmin,Zhang Zexin...&Lin Lizhu.(2023).Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort).Integrative cancer therapies,22,
MLA：
Lin Jietao,et al."Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)".Integrative cancer therapies 22.(2023):15347354231185109
